Available online at: http://www.iajps.com　　　　**Review Article**

PHARMACOLOGICAL APPROACHES IN ALZHEIMER'S DISEASE: CURRENT THERAPEUTIC STRATEGIES AND FUTURE PERSPECTIVES

Avishkar Bhimrao Khadatare[1], Vaibhavi Mohan Mane[2], Saniya Shivaji Kambale[3], Aarti baliram bansode [4], Dr.Rahul ishwara Jadhav[5]

DMKG college of pharmacy, Mangalwedha

Abstract:
Alzheimer's disease is a progressive neurodegenerative disorder and the leading cause of dementia worldwide. The disease is characterized by progressive cognitive decline, memory impairment, and behavioral disturbances. The pathological hallmarks include amyloid-beta plaque deposition, tau protein hyperphosphorylation, oxidative stress, and neuroinflammation leading to neuronal degeneration. Current pharmacological treatments mainly aim to alleviate symptoms and slow disease progression. The most widely used drugs include cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine, along with the NMDA receptor antagonist memantine. In recent years, research has focused on disease-modifying therapies targeting amyloid-beta and tau proteins. Novel approaches including immunotherapy, anti-inflammatory drugs, antioxidants, gene therapy, and nanotechnology-based drug delivery systems are also being investigated. This review highlights the pathophysiology of Alzheimer's disease, currently available pharmacological treatments, emerging therapeutic approaches, and future directions for improved management of this devastating disorder.

**Keywords:** *Alzheimer's disease, neurodegeneration, amyloid beta, cholinesterase inhibitors, memantine, pharmacotherapy.*

Corresponding author:
Aarti baliram bansode,
aaratibandode1211999@gmail.com
DMKG college of pharmacy, Mangalwedha

QR CODE

Please cite this article in press Aarti baliram bansode et al., Pharmacological Approaches In Alzheimer's Disease: Current Therapeutic Strategies And Future Perspectives., Indo Am. J. P. Sci, 2026; 13(03).

NEW STRATEGIES FOR ALZHEIMER'S DISEASE TREATMENT

Caption: Graphical representation of pharmacological approaches in Alzheimer's disease including cholinesterase inhibitors, NMDA receptor antagonists, and emerging therapies targeting amyloid-beta, tau proteins, oxidative stress, and neuroinflammation.

1. INTRODUCTION:

Alzheimer's disease (AD) is a chronic neurodegenerative disorder characterized by progressive loss of cognitive function, memory decline, and impairment in daily activities. It represents the most common form of dementia and accounts for nearly 60–70% of all dementia cases globally. The prevalence of AD is increasing rapidly due to the aging population, making it a major public health challenge.

The disease primarily affects the elderly population and gradually worsens over time. Early symptoms often include mild memory loss and difficulty performing complex tasks. As the disease progresses, patients experience severe cognitive impairment, language difficulties, behavioral changes, and eventually loss of independence.

Despite decades of research, the exact cause of Alzheimer's disease remains incompletely understood. However, several pathological mechanisms have been identified including accumulation of amyloid-beta plaques, formation of neurofibrillary tangles composed of tau proteins, oxidative stress, mitochondrial dysfunction, and chronic neuroinflammation.

Pharmacological management of Alzheimer's disease aims to improve cognitive symptoms, slow disease progression, and enhance quality of life. Although currently available treatments provide only modest symptomatic benefits, ongoing research continues to explore new therapeutic strategies.

Table 1. Classification of Alzheimer's Disease

Type of Alzheimer's Disease	Characteristics	Age of Onset
Early-onset Alzheimer's disease	Rare form caused by genetic mutations (APP, PSEN1, PSEN2 genes)	Before 65 years
Late-onset Alzheimer's disease	Most common form associated with aging and environmental factors	After 65 years
Familial Alzheimer's disease	Inherited form with strong genetic component	Usually early adulthood
Sporadic Alzheimer's disease	Occurs without clear family history	Mostly elderly population

Caption:
Classification of Alzheimer's disease based on age of onset and genetic involvement.

2. Pathophysiology of Alzheimer's Disease
2.1 Amyloid Beta Plaque Formation

One of the most widely accepted hypotheses explaining Alzheimer's disease is the **amyloid cascade hypothesis**. According to this theory, abnormal processing of amyloid precursor protein (APP) results in the formation of amyloid-beta peptides. These peptides aggregate to form extracellular plaques in the brain.

The accumulation of amyloid-beta plaques disrupts neuronal communication and triggers inflammatory responses that contribute to neuronal damage.

Table 2. Major Pathological Features of Alzheimer's Disease

Pathological Feature	Description	Impact on Brain
Amyloid-beta plaques	Extracellular aggregation of amyloid-beta peptides	Disrupt neuronal communication
Neurofibrillary tangles	Intracellular accumulation of hyperphosphorylated tau protein	Causes neuronal damage
Oxidative stress	Excess production of reactive oxygen species	Damages neurons
Neuroinflammation	Activation of microglia and astrocytes	Accelerates neurodegeneration
Synaptic loss	Degeneration of neuronal connections	Memory impairment

Caption:
Major pathological mechanisms contributing to neurodegeneration in Alzheimer's disease.

2.2 Tau Protein Hyperphosphorylation
Tau proteins are responsible for stabilizing microtubules in neuronal cells. In Alzheimer's disease, tau proteins undergo abnormal phosphorylation, leading to the formation of **neurofibrillary tangles**. These tangles interfere with intracellular transport systems and ultimately lead to neuronal death.

2.3 Oxidative Stress
Oxidative stress plays a critical role in the progression of Alzheimer's disease. Increased production of reactive oxygen species damages cellular components including lipids, proteins, and DNA. Neurons are particularly vulnerable to oxidative damage due to their high metabolic activity.

2.4 Neuroinflammation
Chronic activation of microglia and astrocytes in the brain leads to persistent inflammation. This inflammatory response contributes to neuronal degeneration and further accelerates disease progression.

Figure 1. Mechanism of Alzheimer's Disease

Caption: Major pathological mechanisms involved in Alzheimer's disease including amyloid-beta plaque formation, tau protein aggregation, oxidative stress, and neuroinflammation.

3. Current Pharmacological Treatments

3.1 Cholinesterase Inhibitors
Cholinesterase inhibitors are the first-line pharmacological treatment for mild to moderate Alzheimer's disease. These drugs inhibit the enzyme acetylcholinesterase, which breaks down acetylcholine in the brain.

By increasing acetylcholine levels, these drugs improve communication between neurons and enhance cognitive function.
Examples include:
- Donepezil
- Rivastigmine
- Galantamine

These drugs can improve memory, attention, and behavioral symptoms in some patients.

Table 3. Currently Approved Drugs for Alzheimer's Disease

Drug	Drug Class	Mechanism of Action	Therapeutic Use
Donepezil	Acetylcholinesterase inhibitor	Increases acetylcholine levels in brain	Mild to moderate AD
Rivastigmine	Acetylcholinesterase inhibitor	Enhances cholinergic transmission	Mild to moderate AD
Galantamine	Acetylcholinesterase inhibitor	Improves cholinergic neurotransmission	Mild to moderate AD
Memantine	NMDA receptor antagonist	Prevents glutamate excitotoxicity	Moderate to severe AD

Caption:
Currently approved pharmacological agents used in the treatment of Alzheimer's disease.

3.2 NMDA Receptor Antagonists
Memantine is an NMDA receptor antagonist used in moderate to severe Alzheimer's disease. Excessive stimulation of NMDA receptors by glutamate can lead to neuronal damage through excitotoxicity. Memantine helps regulate glutamate activity and protects neurons from excitotoxic damage.

3.3 Combination Therapy
Combination therapy using cholinesterase inhibitors and memantine has shown improved therapeutic outcomes in some patients with advanced Alzheimer's disease. This approach targets multiple pathological pathways simultaneously.

4. Emerging Therapeutic Strategies

4.1 Anti-Amyloid Therapies
Recent research has focused on therapies that target amyloid-beta plaques directly. Monoclonal antibodies such as **aducanumab and lecanemab** are designed to remove amyloid plaques from the brain.

Although these therapies show promise, their clinical benefits are still under investigation.

4.2 Anti-Tau Therapies
Since tau protein aggregation plays a major role in disease progression, researchers are developing drugs that inhibit tau phosphorylation and prevent formation of neurofibrillary tangles.

4.3 Anti-Inflammatory Drugs
Neuroinflammation contributes significantly to Alzheimer's pathology. Anti-inflammatory drugs may reduce microglial activation and slow disease progression.

4.4 Antioxidant Therapy
Antioxidants such as vitamin E, flavonoids, and polyphenols may help reduce oxidative stress and protect neuronal cells from damage.

4.5 Nanotechnology-Based Drug Delivery
Nanotechnology offers innovative strategies for delivering drugs across the blood-brain barrier. Nanoparticles can enhance drug bioavailability and target specific brain regions affected by Alzheimer's disease.

Table 4. Emerging Therapeutic Strategies for Alzheimer's Disease

Therapeutic Approach	Target Mechanism	Example
Anti-amyloid therapy	Reduces amyloid-beta plaque accumulation	Aducanumab
Anti-tau therapy	Prevents tau protein aggregation	Tau inhibitors
Immunotherapy	Stimulates immune system to clear plaques	Monoclonal antibodies
Antioxidants	Reduces oxidative stress	Vitamin E
Anti-inflammatory therapy	Suppresses neuroinflammation	NSAIDs

Caption:
Emerging pharmacological strategies currently under investigation for Alzheimer's disease treatment.

5. Future Perspectives

Advances in molecular biology and neuroscience are opening new possibilities for Alzheimer's disease treatment. Future therapeutic strategies may include:

- Gene therapy targeting disease-causing genes
- Stem cell therapy for neuronal regeneration
- Immunotherapy targeting amyloid and tau proteins
- Personalized medicine approaches

Early diagnosis using biomarkers and neuroimaging techniques may also improve treatment outcomes by enabling intervention at earlier stages of the disease.

Table 5. Advantages and Limitations of Current Alzheimer's Therapies

Therapy Type	Advantages	Limitations
Cholinesterase inhibitors	Improve cognitive function	Limited effect on disease progression
NMDA antagonists	Protect neurons from excitotoxicity	Mild symptomatic improvement
Immunotherapy	Targets underlying pathology	High cost and potential side effects
Antioxidant therapy	Reduces oxidative damage	Limited clinical evidence

Caption:
Comparison of benefits and limitations of available Alzheimer's disease therapies.

6. CONCLUSION:

Alzheimer's disease remains one of the most challenging neurodegenerative disorders affecting the aging population worldwide. Current pharmacological treatments mainly focus on symptomatic relief through cholinesterase inhibitors and NMDA receptor antagonists. However, these therapies provide only limited improvements in cognitive function and do not completely halt disease progression.

Recent advances in understanding the molecular mechanisms underlying Alzheimer's disease have led to the development of novel therapeutic approaches targeting amyloid-beta plaques, tau protein aggregation, oxidative stress, and neuroinflammation. Emerging therapies such as immunotherapy, nanotechnology-based drug delivery systems, and gene therapy hold significant promise for future treatment strategies.

Continued research is essential to develop effective disease-modifying therapies that can slow or prevent the progression of Alzheimer's disease. Early diagnosis, improved therapeutic interventions, and personalized treatment approaches may significantly improve patient outcomes and quality of life.

REFERENCES:

1. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement. 2023.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease. Science. 2002.
3. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010.
4. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001.
5. Lane CA, Hardy J, Schott JM. Alzheimer's disease. Eur J Neurol. 2018.
6. Ballard C, Gauthier S. Alzheimer's disease. Lancet. 2011.
7. Cummings J. Alzheimer's disease drug development pipeline. Alzheimers Dement. 2022.
8. Scheltens P, et al. Alzheimer's disease. Lancet. 2021.
9. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. Mol Neurodegener. 2019.
10. Hampel H. The amyloid-beta pathway in Alzheimer's disease. Nat Rev Neurol. 2021.
11. Wang JZ. Tau protein in Alzheimer's disease. Neurosci Bull. 2013.
12. Butterfield DA. Oxidative stress in Alzheimer's disease. Brain Res Bull. 2002.
13. Heneka MT. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015.
14. Birks JS. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database. 2006.
15. Reisberg B. Memantine therapy in Alzheimer's disease. N Engl J Med. 2003.
16. Sevigny J. Aducanumab reduces amyloid plaques. Nature. 2016.
17. Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology. Cell. 2019.
18. Knopman DS. Alzheimer disease therapy and future directions. Nat Rev Neurol. 2021.
19. Atri A. Current and future treatments in Alzheimer's disease. Semin Neurol. 2019.
20. Cummings JL. New therapeutic approaches for Alzheimer's disease. Nat Rev Drug Discov. 2019.